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Pancreatic islet regeneration: Therapeutic 
potential, unknowns and controversy
Glucose homeostasis in mammals is primarily maintained by the insulin-secreting β-cells contained within 
pancreas-resident islets of Langerhans. Gross disruption of this glucose regulation as a result of pancreatic 
dysfunction frequently results in diabetes, which is currently a major health concern in South Africa, as 
well as globally. For many years, researchers have realised that the pancreas, and specifically the islets of 
Langerhans, have a regenerative capacity, as islet mass has frequently been shown to increase following 
induced pancreatic injury. Given that gross β-cell loss contributes significantly to the pathogenesis of both 
type 1 and type 2 diabetes, endogenous pancreatic islet regeneration has been investigated extensively as 
a potential β-cell replacement therapy for diabetes. From the extensive research conducted on pancreatic 
regeneration, opposing findings and opinions have arisen as to how, and more recently even if, pancreatic 
regeneration occurs following induced injury. In this review, we outline and discuss the three primary 
mechanisms by which pancreatic regeneration is proposed to occur: neogenesis, β-cell replication and 
transdifferentiation. We further explain some of the advanced techniques used in pancreatic regeneration 
research, and conclude that despite the technologically advanced research tools available to researchers 
today, the mechanisms governing pancreatic regeneration may remain elusive until more powerful 
techniques are developed to allow for real-time, live-cell assessment of morphology and gene expression 
within the pancreas. 
Diabetes: Therapies and challenges
The prevalence of diabetes and its comorbidities, such as cardiovascular disease, is increasing rapidly both globally 
and in South Africa.1 It is currently estimated that 347 million people worldwide suffer from the disease and the 
prevalence of diabetes is predicted to double between 2005 and 2030.2 Indeed, in a recent comprehensive survey 
on health and nutrition in South Africa, diabetes was diagnosed in 9.6% of the survey participants (aged ≥15 
years),3 which, based on South Africa’s current population, equates to ~5 million people living with the disease. Of 
particular concern is that the prevalence in some demographic groups far exceeds the national average: diabetes 
was diagnosed in as much as 30.7% of the Asian / Indian study participants.3 This malady exerts a considerable 
burden of disease, which will increase with its rapidly escalating prevalence.
Diabetes is commonly subdivided into two types, with type 1 diabetes (T1D) believed to account for only 5–10% of 
all diabetes cases4, although little data are currently available regarding the prevalence of T1D in South Africa5. The 
insulin deficiency associated with T1D is caused by an autoimmune destruction of insulin-producing pancreatic 
β-cells.6 The hyperglycaemia and ketosis resulting from gross β-cell depletion in T1D patients are currently 
treated with insulin replacement,7 and research into potential T1D therapeutics is therefore commonly focused on 
developing strategies to eliminate the dependence of patients on exogenous insulin. One such approach, which 
represents a major advancement in diabetes therapy, is islet or pancreas transplantation. Transplantation of either 
whole pancreata or isolated islets as a means to regain pancreatic endocrine function has been successfully 
used to reverse T1D; however, limitations – including an insufficient number of donor organs, poor cell viability 
and undesirable effects of the accompanying immunosuppressive drugs – have meant that transplantation is 
currently not a feasible and sustainable solution.8,9 Although type 2 diabetes (T2D) is generally characterised by 
hyperglycaemia primarily resulting from insulin resistance, insufficient insulin production as a result of the loss of 
β-cells, as in T1D, is also important in the aetiology of the disease10, as β-cell function and mass are known to be 
reduced in T2D patients11. 
To address the limitations associated with the management of diabetes, such as the exogenous insulin-dependence 
of patients as well as the shortcomings of islet or pancreas transplantation, possible alternative sources of β-cells 
for replacement therapy have been investigated. These alternatives include the stimulation of the pancreas to 
promote the endogenous regeneration of viable β-cells. With a view to future pharmacological or cell therapy 
interventions, researchers have looked to in-utero pancreatic organogenesis to ascertain which molecular pathways 
may be important for generating increased islet mass. In particular, the temporal expression of transcription factors 
involved in pancreatic cell fate determination has been investigated and characterised. 
In-utero pancreatic development
Knowledge of the in-utero development of the mammalian pancreas, and in particular of the origin and development 
of the islets of Langerhans and β-cells, provides a starting point for investigations into potential regenerative 
processes in the adult pancreas. All exocrine and endocrine cell types of the pancreas originate from a common 
pool of progenitor cells in the gut endoderm of the embryo. A pancreatic bud forms from the endoderm, and 
subsequently expands and forms branched structures which eventually form the pancreatic ducts.12 During the 
extension of these branches, clusters of endocrine cells bud off and aggregate to form the islets of Langerhans.13 
A brief overview of the in-utero development of islet cells and the transcription factors involved in this process is 
depicted in Figure 1.
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Figure 1: Brief overview of the regulation of in-utero β-cell development 
by transcription factors during pancreatic organogenesis. 
(1) Mesenchymal Ipf1-expressing cells in the gut give rise to 
all pancreatic cells including exocrine endothelial cells (EECs). 
(2) A subset of EECs which express Ngn3 then differentiate into 
the five cell types constituting the islets of Langerhans. (3) The 
development of β-cells from Ngn3+progenitor cells requires 
the expression of numerous transcription factors including 
MafB, Pax1, Isl1, Pax4, Pax6, Hlxb9, Nkx2.2 and Nkx6.1.
The transcription factor Ipf1 (insulin promoter factor 1, Pdx1 in 
rodents) is known to play a major role in pancreatic specification and 
growth in early embryonic development, and indeed, lineage-tracing 
experiments have shown that all pancreatic cells, both exocrine and 
endocrine, arise from Ipf1-expressing progenitor cells.14 Further along in 
pancreatic development, the endocrine portion of the pancreas (islets of 
Langerhans) is formed from a subset of pancreatic duct endothelial cells 
expressing a second transcription factor central to islet development, 
namely neurogenin 3 (Ngn3): Ngn3-expressing progenitors differentiate 
into the five endocrine cell types (α-, β-, δ-, ε- and PP-cells), which 
subsequently separate from the endothelium and cluster to form the 
islets of Langerhans.15,16 Of the five islet cell types, α- and β-cells are 
the most abundant17; and while murine islets consist of a β-cell core 
surrounded by a mantle of α- and δ-cells, the α-, β- and δ-cells are 
dispersed throughout human and non-human primate islets18. 
The development of β-cells, in particular from Ngn3+ cells, is regulated 
by the Pax4 gene19, a member of the homeobox transcription factor 
gene family which comprises a large and diverse group of genes that 
play an important role in embryonic development20. Pax4 expression is 
known to peak during in-utero β-cell development21, and, in a knockout 
study, Pax4-deficient mice showed significantly diminished β-cell 
development19. The absence of Pax4 expression in mature islet cells is 
indicative of the importance of Pax4 expression to β-cell development, 
in particular, rather than β-cell function or maintenance.21 
Pancreatic regeneration
Discovery and models
Since the 1960s, many reports have demonstrated in-vivo manipulation 
of the pancreas by mechanical stress (injury) to stimulate the regeneration 
of damaged tissue and, importantly, also an increase in islet mass in the 
pancreas. Ligation or partial occlusion of the main pancreatic duct22–25 
as well as incomplete pancreatectomy26,27 have been shown to result in 
pancreatic regeneration – observed as increased mass of the endocrine 
portion (islets) of pancreata following induced injury. In the 1970 study 
by Boquist and Edström22, ligation of the main pancreatic duct in rats 
resulted in degeneration of acinar cells, with no signs of regeneration of 
this exocrine moiety of the pancreas. There was, however, an increase in 
endocrine cells following duct ligation, specifically by endocrine clusters 
seen to bud off from proliferating ductules and develop into islets. 
Similarly, Rosenberg and colleagues23 observed the formation of new 
islets from hyperplasic (proliferating) ductules after partial occlusion 
of the pancreatic ducts of hamsters by wrapping a thin cellophane 
strip around the head of the pancreas. In more significant pancreatic 
injury (90% pancreatectomy in rats), pronounced regeneration of both 
the endocrine and exocrine pancreatic tissues was observed 8 weeks 
subsequent to surgeries.26 All these studies involved subjecting the 
pancreata of study animals to prolonged mechanical stress; however, 
it was later shown that even brief occlusion of the main pancreatic duct 
(by gently squeezing the pancreas for 60 s) in rats results in duct cell 
proliferation and signs of islet regeneration24, as well as overall increased 
endocrine mass (by 80%) 56 days after surgery, suggestive of islet 
neogenesis25. The fact that apparent islet neogenesis was observed even 
after only very brief occlusion of the pancreatic duct suggested that the 
signalling events triggering these regenerative processes in response to 
pancreatic injury occur immediately at the initiation of injury. 
Proposed mechanisms of regeneration
The observations described above lead into key and currently unresolved 
questions regarding the mechanisms and processes governing islet 
regeneration. Islet regeneration, and specifically regeneration of β-cells 
following pancreatic injury, has generally been attributed to one of three 
mechanisms: transdifferentiation of non-endocrine cells into β-cells, 
neogenesis of β-cells from progenitor cells, or replication of existing 
β-cells (Figure 2); however, contradictory opinions and data surrounding 
these theories are plentiful.
DC
PC 3a
3b
4
1 2
β
β
Figure 2: Proposed mechanisms of β-cell regeneration. β-Cells (β) have 
been proposed to regenerate via one of several mechanisms: 
(1) neogenesis via differentiation of specialised progenitor 
cells (PC); (2) transdifferentiation of differentiated non-β-cells 
(DC) to β-cells, in which DCs are either exocrine (acinar or 
ductal) or endocrine (α-cells) non-β-cells undergoing either 
exocrine-to-endocrine or inter-endocrine transdifferentiation, 
respectively; (3) de-differentiation of differentiated non-β-cells 
to progenitor-type cells (3a) and subsequent re-differentiation 
of these progenitor-type cells to β-cells (3b); or (4) replication 
or self-renewal of existing, differentiated β-cells.
Transdifferentiation
As islet cells originate from a subset of duct cells during pancreatic 
organogenesis (as described above), transdifferentiation has been 
investigated as a possible mechanism by which islet regeneration 
occurs in the adult pancreas. In adult rats subjected to pancreatic duct 
ligation, transdifferentiation has been identified in the pancreas in the 
form of cells co-expressing markers from more than one terminally 
differentiated cell type, indicating a mixed lineage. These cells include 
those expressing both epithelial and β-cell markers; cells co-expressing 
epithelial and α-cell markers; duct cells expressing GLUT-2, the β-cell-
specific glucose transporter protein28; or intra- and extra-islet cells 
co-expressing acinar cell and β-cell markers29. In these and other 
studies,30–32 increased islet cell number following pancreatic injury 
was thus attributed mainly to the transdifferentiation of non-endocrine 
(acinar or duct) cells to endocrine (α- or β-) cells. In an in-vitro study, 
AR42J acinar-derived amylase-secreting cells were converted to 
insulin-secreting cells by treatment with the growth factors betacellulin 
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and activin A,33 and although insulin secretion by these cells does not 
confirm their identity as β-cells, the observed conversion is suggestive 
of exocrine-to-endocrine transdifferentiation. In a more recent lineage-
tracing study on transgenic mice subjected to dipthera toxin-induced 
β-cell ablation, inter-endocrine transdifferentiation was also suggested 
to occur: new β-cells were identified as arising from α-cells.34 
Desai and colleagues35 refuted the hypothesis that exocrine acinar cells 
transdifferentiate into endocrine β-cells based on the findings of their in 
vivo lineage-tracing experiments in which the acinar cells of transgenic 
mice were genetically labelled. This labelling strategy allowed for the 
progeny of these cells to be identified, thereby enabling the investigators 
to identify cells of acinar origin. Various models of pancreatic injury were 
used to induce regeneration, after which a lack of labelled endocrine 
cells was observed, leading the authors to conclude that ‘acinar cells 
do not normally transdifferentiate into islet beta cells in vivo in adult 
mice’35. The findings of another genetic labelling-based study further 
countered the notion of transdifferentiation being the mechanism by 
which islet regeneration occurs by indicating that β-cells only arise from 
duct epithelial cells during embryogenesis, and that these epithelial cells 
do not significantly contribute to endocrine or acinar cell populations 
after birth.36 
The findings described here clearly demonstrate that reports regarding 
transdifferentiation as a mechanism by which pancreatic regeneration 
occurs are as contradictory as they are plentiful. 
Neogenesis from specialised progenitors
A population of specialised progenitor cells in the pancreas that can give 
rise to new β-cells would be extremely valuable for the development 
of endogenous cell therapies for the treatment of diabetes-associated 
β-cell depletion. Such a cell population could conceivably either be 
isolated, expanded ex vivo and used for transplantation or alternatively 
be stimulated to produce new β-cells in vivo. Thus far, however, whether 
or not such a specialised progenitor cell population exists in the pancreas 
remains unclear despite a number of reports in support of the existence 
of such cells. In corroboration with the existence of progenitor cells 
within the pancreas, flow cytometry has been used to identify a side 
population of cells in the murine pancreas which has been described 
as a putative stem cell population. These cells, identified as stem cells 
based on their ability to expel the Hoechst 33342 DNA-binding dye, were 
shown to undergo hyperplasia in vivo after β-cell or pancreas injury and, 
upon induction, the cells proliferated and differentiated in vitro giving rise 
to endocrine cells that exhibited glucose-stimulated insulin secretion.37 
These findings led the authors to conclude that progenitor cells that 
give rise to endocrine cells exist within the pancreas, a conclusion 
also reached by other researchers who identified endogenous β-cell 
progenitors on the basis of the expression of the islet cell-specific 
transcription factor Ngn3: Ngn3-expressing cells located in the ductal 
lining of the pancreas were shown to be multi-potent progenitor cells 
with the ability to give rise to new glucose-responsive β-cells both in 
situ and in vitro.38 Very small embryonic-like stem cells (VSELs), a novel 
type of pluripotent stem cell reported to exist in various adult murine 
organs including the pancreas,39 were recently reported to mobilise to 
the pancreas following partial pancreatectomy in mice. These VSELs 
reportedly differentiated into progenitor cells expressing Pdx1 (the 
transcription factor expressed by progenitor cells that differentiate into 
all pancreatic cell types during organogenesis), potentially giving rise to 
new acinar and islet cells.40 
Based on the findings of another study using a partial pancreatectomy 
model in rats, islet regeneration has been suggested to occur via initial 
de-differentiation of duct cells to progenitor-type cells, followed by re-
differentiation of these cells, which ‘recapitulate aspects of embryonic 
pancreas differentiation’ to facilitate pancreatic regeneration41 – a 
mechanism which can be classed as neogenesis or transdifferentiation, 
or indeed a combination of the two.
A report opposing the hypothesis that β-cell regeneration following 
pancreatic injury occurs via neogenesis was recently published: the 
results of lineage-tracing experiments carried out using various models 
of β-cell loss in the adult murine pancreas led the authors to conclude 
that little to no β-cell neogenesis occurs in the adult pancreas under 
normal and pathological (partial pancreatectomy, duct ligation or 
treatment with β-cell-specific toxins) conditions.42
β-cell replication
The controversies and conflicting opinions within the field of islet 
regeneration are clearly demonstrated by the literature on β-cell 
replication as the mechanism driving β-cell maintenance and/or 
regeneration: ‘Adult pancreatic beta-cells are formed by self-duplication 
rather than stem-cell differentiation’43; ‘β-cell replication is the primary 
mechanism subserving the postnatal expansion of β-cell mass in 
humans’44 and ‘β-cell growth and regeneration: Replication is only part 
of the story’45 are the titles of just some of these publications. 
It was initially believed that significant β-cell proliferation does not occur 
after the initial periods of β-cell mass growth during the neonatal and 
infancy stages of development, and that β-cell mass is not replenished or 
maintained by β-cell proliferation.46-48 Studies on β-cell replication have 
thus generally been carried out to assess not only β-cell replenishment 
following pancreatic injury, but also increases and maintenance of β-cell 
mass under normal physiological conditions. Similar to the lineage-
tracing experiments carried out by Desai and colleagues35 (described 
previously), Dor et al.43 made use of a transgenic mouse model and a 
tamoxifen-inducible Cre/lox system to integrate genes into the genome 
by which β-cells were specifically labelled with a histochemically 
detectable, heritable label. Subsequent to removal of the initial ‘pulse’ 
(tamoxifen treatment), only pre-labelled β-cells and progeny of such 
cells would carry the detectable label, allowing newly formed β-cells 
to be identified as being β-cell-derived or non-β-cell-derived. These 
genetic labelling experiments led the authors to conclude that, during 
normal adult life or following pancreatectomy in the murine pancreas, 
adult β-cells are formed or replenished by replication rather than by 
islet neogenesis or differentiation of stem cells.43 In agreement with the 
conclusion reached by Dor and colleagues, a later human study in which 
β-cell mass was assessed using computer tomography techniques 
revealed that β-cell mass expansion during infancy, the period during 
which β-cell growth rates were found to be highest, occurs primarily 
via β-cell replication44; and in a transgenic mouse model, near-complete 
β-cell ablation was followed by full recovery of the pancreas, which 
was described to occur via β-cell replication within existing islets 
rather than islet neogenesis49. In an extensive review by Bonner-Weir 
and colleagues45, β-cell replication and neogenesis as mechanisms of 
pancreatic regeneration or postnatal islet growth are described as not 
being mutually exclusive. The authors go on to review the many reports 
on pancreatic regeneration and conclude that both neogenesis and 
β-cell replication contribute to β-cell mass maintenance, and that both 
these mechanisms have the potential to be harnessed for therapeutic 
applications.45
Doubt shed on regeneration
Controversy surrounding β-cell regeneration has recently extended 
from differing opinions on the mechanisms allowing for regeneration, 
to doubts being raised as to whether regeneration following pancreatic 
injury does in fact occur at all: Rankin et al.50 recently reported on 
extensive experiments carried out in an adult mouse model which, in 
agreement with the report by Xiao and colleagues42, show that adult 
β-cells do not develop from specialised pancreas-resident progenitor 
cells following pancreatic injury and, importantly, also that new β-cells 
are not generated following pancreatic duct ligation.50 The authors of 
this report attribute the apparent regeneration that has frequently been 
described for similar pancreatic injury models to quantitative artefacts 
and variable recovery of pancreatic tissue; an extensive morphometric 
assessment of the entire murine pancreas in Rankin et al.’s study 
indicates that β-cell mass is unaltered in the ligated pancreas compared 
with sham-operated tissue and therefore that injury of the adult murine 
pancreas does not induce β-cell regeneration.50 
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Both Xiao et al.42 and Rankin et al.50 conclude that β-cell neogenesis 
does not occur following pancreatic injury; however, in both these 
studies, the expression of the islet-specific transcription factor Ngn3 
was shown to be increased following pancreatic injury. Kushner and 
colleagues attributed the observed induction of Ngn3 expression by 
ligation in their study to an ‘artefact due to differences in RNA recovery 
from injured compared with uninjured pancreas’50, while damage to the 
injured portion of the pancreas (specifically exocrine cell contents and 
various inflammatory factors) was proposed to induce an up-regulation 
of Ngn3 expression in existing β-cells by Xiao and colleagues42. 
Perspective
In this brief review we have presented the diverse and often contradictory 
findings of some of the many investigations into pancreatic regeneration 
carried out over the last five decades. It is clear from these studies 
that putative islet regeneration is a complex, poorly understood and 
controversial research area, but the potential benefits of understanding 
and possibly harnessing the processes involved are immense. Despite 
recent reports contesting the existence of β-cell regeneration, a lot of 
unknowns in this field remain to be clarified: Why do different studies 
obtain vastly different results when investigating the same models and 
systems? If pancreatic regeneration does not take place, why is Ngn3 
up-regulated following pancreatic injury? 
Although sophisticated techniques available to us today, such as genetic 
lineage-tracing technology, are extremely powerful, they too are limited. 
In the case of investigations into pancreatic injury-induced events, the 
ideal scenario would be one in which cells can be monitored in real 
time within the pancreas, simultaneously assessing both morphological 
changes and gene expression. Although three-dimensional microscopy 
and the culturing of whole or partial fragments of tissues have advanced 
considerably in recent years, this ideal is still beyond our capabilities. Until 
such time that technological advances will allow for such assessments 
to be carried out, definitive mechanisms that potentially stimulate an 
increase in β-cell mass triggered by pancreatic injury remain elusive. 
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